Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146078 · ClinicalTrials.gov registry record
Rate of Progression in USH2A-related Retinal Degeneration
A clinical trial of Usher Syndrome, Type 2A and Retinitis Pigmentosa 39, sponsored by Jaeb Center for Health Research.
- Active
- Registry status
- 127
- Enrollment target
- 14
- Study locations
NCT03146078: Active study of Usher Syndrome, Type 2A and Retinitis Pigmentosa 39, sponsored by Jaeb Center for Health Research.
NCT03146078 is a study of Usher Syndrome, Type 2A and Retinitis Pigmentosa 39 that is active but no longer recruiting, run by Jaeb Center for Health Research. The registered enrollment target is 127 participants. The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03146078, a study of Usher Syndrome, Type 2A and Retinitis Pigmentosa 39, is active but no longer recruiting, sponsored by Jaeb Center for Health Research.
- ACTIVE NOT RECRUITING
- Registry status
- 127 participants
- Enrollment target
- 14
- Study locations
Study Summary
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39). RUSH2A Extension Study: The purpose of this addendum is to extend RUSH2A to 7- and 9-year visits, with the goal to use longer term data to further develop and support early candidate endpoints as possible clinical trial outcomes.
Primary Outcome
Measured by static perimetry with topographic analysis (Hill of Vision)
Conditions Studied
Study Locations (14)
Other
- Hospital for Sick Children - Toronto
- Centre hospitalier National d'Ophtalmologie des Quinze-Vingts - Paris
- University of Tubingen - Tübingen
- Radboud University - Nijmegen
- Moorfields Eye Hospital - London
Texas
- Retina Foundation of the Southwest - Dallas
- Baylor Eye Physicians and Surgeons - Houston
California
- University of California, San Francisco - San Francisco
Florida
- Vitreo-Retinal Associates - Gainesville
Maryland
- Wilmer Eye Institute at Johns Hopkins - Baltimore
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- Kellogg Eye Center, University of Michigan - Ann Arbor
Oregon
- OHSU Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2017-08-11 |
| Est. Completion | 2029-12 |
What the registry record for NCT03146078 still lists
NCT03146078 is an observational study that tracks outcomes without assigning an intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Usher Syndrome, Type 2A appearing as the primary indexed condition, and to 0 interventions.
NCT03146078 lists 14 locations in 9 states (Other, Texas, California).
Frequently Asked Questions
What is clinical trial NCT03146078 about?
NCT03146078 is a clinical study titled "Rate of Progression in USH2A-related Retinal Degeneration". The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39)...
What is the current status of trial NCT03146078?
This trial is currently active not recruiting. The enrollment target is 127 participants. The study started on 2017-08-11. Estimated completion is 2029-12.
What conditions does trial NCT03146078 study?
This clinical trial studies the following conditions: Usher Syndrome, Type 2A, Retinitis Pigmentosa 39.
Who is sponsoring clinical trial NCT03146078?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03146078 being conducted?
This trial has 14 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI